Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK begins shipments of Fluarix and FluLaval to US customers
The FDA’s Center for Biologics Evaluation and Research released the first lots of Fluarix and FluLaval, allowing distribution to begin. GlaxoSmithKline (GSK) said that it plans to supply
The FDA’s Center for Biologics Evaluation and Research released the first lots of Fluarix and FluLaval, allowing distribution to begin. GlaxoSmithKline (GSK) said that it plans to supply
ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. With the initiation of the Phase I trial, MM-121 becomes
The agreement will allow RFI to market products under the registered trademark AC-11 and capitalize on the scientifically validated qualities of the patented AC-11 compound. In third party
Under the terms of the agreement, Huifeng said that it is to deliver 62 metric tons of glucuronolactone, a naturally occurring chemical compound which has become a popular
The new trial is the second Phase II study evaluating bavituximab in advanced breast cancer patients, and Peregrine also is conducting a third Phase II combination therapy trial
Alnylam said that its scientists will work closely with the laboratory of Marino Zerial, whose team is internationally recognized as being at the forefront of the intracellular trafficking
The Lupus biomarker panel has been developed using Sense Proteomic’s proprietary protein array technology that permits rapid identification of autoantibody biomarkers for cancer and autoimmune diseases, the company
The trial has two components. The first is an open-label, dose-escalating, non-randomized study of Reolysin given intravenously with docetaxel every three weeks. Standard dosages of docetaxel were delivered
The company released top-line results from its 163 patient, double-blind, placebo-controlled trial of Trizytek, an enzyme replacement therapy for patients with pancreatic insufficiency. Trizytek is a stable and
Perrigo said that it won a patent challenge for Famotidine Complete, the national brand equivalent to Pepcid Complete marketed by Johnson & Johnson – Merck Consumer Pharmaceuticals. The